R. Bataille and J. Harousseau, Multiple Myeloma, New England Journal of Medicine, vol.336, issue.23, pp.1657-1664, 1997.
DOI : 10.1056/NEJM199706053362307
URL : https://hal.archives-ouvertes.fr/inserm-00479729

M. Attal, J. Harousseau, and A. Stoppa, A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, New England Journal of Medicine, vol.335, issue.2, pp.91-97, 1996.
DOI : 10.1056/NEJM199607113350204

S. Lenhoff, M. Hjorth, and E. Holmberg, Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group, Blood, vol.95, pp.7-11, 2000.

M. Attal, J. Harousseau, and T. Facon, Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2495-502, 2003.
DOI : 10.1056/NEJMoa032290

P. Moreau, T. Facon, and M. Attal, Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial, Blood, vol.99, issue.3, pp.731-735, 2002.
DOI : 10.1182/blood.V99.3.731

D. Sieghel, K. Desikan, and J. Mehta, Age is not a prognostic variable with autologous transplantation for multiple myeloma, Blood, vol.93, pp.51-54, 1999.

B. Barlogie, S. Jagannath, and D. Vesole, Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma, Blood, vol.89, pp.789-93, 1997.

B. Barlogie, S. Jagannath, and K. Desikan, Total therapy with tandem transplants for newly diagnosed multiple myeloma, Blood, vol.93, pp.55-65, 1999.

H. Goldschmidt, G. Egerer, and A. Ho, Autologous and allogeneic stem cell transplantation in multiple myeloma, Bone Marrow Transplantation, vol.25, issue.2, pp.25-31, 2000.
DOI : 10.1038/sj.bmt.1702348

J. Rossi, E. Legouffe, and N. Fegueux, Autologous transplantation (AT) of CD34+ peripheral blood progenitor cells (PBPC) after double (D) high dose chemotherapy (HDC) in multiple myeloma (MM) is followed by severe immunodeficiency (ID) and high production of interleukin-6 (IL-6) related-C Reactive Protein (CRP) requiring additive immunotherapy (IT)

R. Lemoli, G. Martinelli, and E. Zamagni, Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy, Blood, vol.95, pp.2234-2239, 2000.

A. Stewart, R. Vescio, and G. Schiller, Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial, Journal of Clinical Oncology, vol.19, issue.17, pp.3771-3779, 2001.
DOI : 10.1200/JCO.2001.19.17.3771

M. Kawano, T. Hirano, and T. Matsuda, Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas, Nature, vol.332, issue.6159, pp.83-87, 1988.
DOI : 10.1038/332083a0

B. Klein, X. Zhang, Z. Lu, and R. Bataille, Interleukin-6 in multiple myeloma, Blood, vol.85, pp.863-872, 1995.
URL : https://hal.archives-ouvertes.fr/inserm-00136072

B. Klein, X. Zhang, J. M. Content, and J. , Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989.

B. Klein, X. Zhang, and J. M. , Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma, Eur Cytokine Netw, vol.1, pp.193-201, 1990.

X. Zhang, J. Gaillard, and N. Robillard, Reproducible obtaining myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

M. Portier, G. Rajzbaum, and X. Zhang, In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma, European Journal of Immunology, vol.76, issue.1, pp.1759-1762, 1991.
DOI : 10.1002/eji.1830210727

P. Greipp, T. Leong, and J. Benett, Plasmablastic morphology, an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E 9486 report by the ECOG Myeloma Laboratory Group, Blood, vol.91, pp.2501-2507, 1998.

R. Stasi, M. Brunetti, A. Parma, D. Giulio, and C. , The prognostic value of soluble interleukin- 6 receptor in patients with multiple myeloma, Cancer, vol.82, pp.1869-1862, 1998.

B. Klein, J. Widjenes, and X. Zhang, Murine anti-IL-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, vol.78, pp.1198-1204, 1991.

R. Bataille, B. Barlogie, and Z. Lu, Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, vol.86, pp.685-691, 1995.

Z. Lu, H. Brailly, J. Rossi, J. Wijdenes, R. Bataille et al., Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis, Cytokine, vol.5, issue.6, pp.578-582, 1993.
DOI : 10.1016/S1043-4666(05)80007-9

Z. Lu, H. Brailly, J. Wijdenes, R. Bataille, J. Rossi et al., Measurement of whole body interleukin-6 (IL-6) production : prediction of the efficacy of anti-IL-6 treatments, Blood, vol.86, pp.3124-3131, 1995.

J. Blay, J. Rossi, J. Widjenes, and C. Menetrier-caux, Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma, International Journal of Cancer, vol.86, issue.3, pp.424-430, 1997.
DOI : 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R

M. Frassanito, A. Cussmai, G. Iodice, and F. Dammacco, Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis, Blood, vol.97, issue.2, pp.483-489, 2001.
DOI : 10.1182/blood.V97.2.483

N. Borsellino, A. Belldegrun, and B. Bonavida, Endogenous interleukin-6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines, Cancer Res, vol.55, pp.4633-4639, 1995.

Y. Mizutani, B. Bonavida, and Y. Koishihara, Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or antiinterleukin 6 receptor monoclonal antibody, Cancer Res, vol.55, pp.590-596, 1995.

B. Klein and H. Brailly, Cytokine-binding proteins: stimulating antagonists, Immunology Today, vol.16, issue.5, pp.216-220, 1995.
DOI : 10.1016/0167-5699(95)80161-8

F. Montero-julian, B. Klein, E. Gautherot, and H. Brailly, Pharmacokinetic study of anti- interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies, Blood, vol.85, pp.917-924, 1995.

J. Blade, D. Samson, and D. Reece, Criteria for evaluating disease response and progression in patients with multiple myeloma traeted with high-dose therapy and haematopoietic stem cell transplantation. Myeloma subcommittee of the EBMT, European bone Marrow Transplant

J. Widjenes, C. Clement, and B. Klein, Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies, Mol Immunol, vol.28, pp.1183-1192, 1991.

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, p.457, 1958.
DOI : 10.1214/aoms/1177731566

M. Steffen, M. Durken, and U. Pichlmeier, Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment, Bone Marrow Transplant, vol.18, pp.301-307, 1996.

G. Veldhuis, P. Willemse, and D. Sleijfer, Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer., Journal of Clinical Oncology, vol.13, issue.10, pp.2585-93, 1995.
DOI : 10.1200/JCO.1995.13.10.2585

M. Trickha, R. Corringham, B. Klein, and J. Rossi, Targetted anti-interleukin-6 monoclonal antibody therapy for cancer: review of the rationale and clinical evidence, Clin Cancer Res, vol.9, pp.4653-4665, 2003.

J. Beck, S. Hsu, and J. Wijdenes, Brief Report, Obstetrical & Gynecological Survey, vol.47, issue.11, pp.602-605, 1994.
DOI : 10.1097/00006254-199211000-00021

D. Emilie, J. Widjenes, and C. Gisselbrecht, Administration of an anti-interleukin-6

E. Legouffe, J. Liautard, and J. Gaillard, Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6, Clinical & Experimental Immunology, vol.34, issue.Suppl. 1, pp.323-329, 1994.
DOI : 10.1111/j.1365-2249.1994.tb06145.x

J. Castell, M. Gomez-lechon, and M. David, Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6, Hepatology, vol.168, issue.5, pp.1179-1186, 1990.
DOI : 10.1002/hep.1840120517

O. Kollet, R. Aviram, and J. Chebath, The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+CD38-/low cells capable of repopulating severe combined immunodeficiency mice, Blood, vol.94, pp.923-931, 1999.

L. Sun, X. Liu, and L. Qiu, Administration of plasmid DNA expressing human interleukin-6 significantly improves thrombocytopoiesis in irradiated mice, Ann Hematol, vol.80, pp.567-572, 2001.

A. Kaser, G. Brandacher, and W. Steurer, Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis, Blood, vol.98, issue.9, pp.2720-2725, 2001.
DOI : 10.1182/blood.V98.9.2720

T. Efferth, U. Fabry, and R. Osieka, Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells, Anticancer Res, vol.22, pp.231-234, 2002.

M. Rowley, P. Liu, and B. Van-ness, Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin-6, dexamethasone, doxorubicin and melphalan, Blood, vol.96, pp.3175-3180, 2000.

E. Tegg, A. Griffiths, and R. Lowenthal, Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation, Bone Marrow Transplantation, vol.28, issue.10, pp.929-933, 2001.
DOI : 10.1038/sj.bmt.1703272

P. Moreau, N. Milpied, and B. Mahé, Melphalan 220???mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma, Bone Marrow Transplantation, vol.23, issue.10, pp.1003-1006, 1999.
DOI : 10.1038/sj.bmt.1701763

B. Durie and S. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.126, issue.3, pp.842-854, 1975.
DOI : 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U